Exosomes are possibly used as a tool of immune regulation during the dendritic cell-based immune therapy against HIV-I

Medical Hypotheses

Volumn 95, Issue , 2016, Pages 67-70

  Ellwanger, Joel Henrique ^a   Crovella, Sergio ^b   dos Reis, Edione Cristina ^c   Pontillo, Alessandra ^c   Chies, José Artur Bogo ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; DNA BINDING PROTEIN; ESCRT PROTEIN; IMMUNOLOGIC FACTOR; TRANSCRIPTION FACTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL MATURATION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL BASED IMMUNE THERAPY; DOWN REGULATION; EXOSOME; EXOSOME RELEASE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; MONOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TSG101 GENE; ADULT; BLOOD; CYTOLOGY; DENDRITIC CELL; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE SYSTEM; MALE; METABOLISM; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DNA-BINDING PROTEINS; DOWN-REGULATION; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; EXOSOMES; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; MONOCYTES; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84988353640     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2016.09.005     Document Type: Article

References (30)

1. [1] García, F., Routy, J.P., Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 29 (2011), 6454–6463.
2. [2] García, F., Plana, M., Climent, N., León, A., Gatell, J.M., Gallart, T., Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vaccin Immunother 9 (2013), 2445–2452.
3. [3] Lu, W., Arraes, L.C., Ferreira, W.T., Andrieu, J.M., Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10 (2004), 1359–1365.
4. [4] Segat, L., Brandão, L.A.C., Guimarães, R.L., et al. Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment. Vaccine 28 (2010), 2201–2206.
5. [5] Ferreira, V., Moura, P., Crovella, S., et al. The influence of HIV-1 subtype in the response to therapeutic dendritic cell vaccine. Open AIDS J 6 (2012), 289–292.
6. [6] Moura, R., Pontillo, A., D'Adamo, P., Pirastu, N., Campos Coelho, A., Crovella, S., Exome analysis of HIV patients submitted to dendritic cells therapeutic vaccine reveals an association of CNOT1 gene with response to the treatment. J Int AIDS Soc, 17, 2014, 18938.
7. [7] Pontillo, A., Da Silva, R.C., Moura, R., Crovella, S., Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1. Hum Vaccin Immunother 10 (2014), 512–518.
8. [8] McCoy-Simandle, K., Hanna, S.J., Cox, D., Exosomes and nanotubes: control of immune cell communication. Int J Biochem Cell Biol 71 (2016), 44–54.
9. [9] Konadu, K.A., Chu, J., Huang, M.B., et al. Association of cytokines with exosomes in the plasma of HIV-1-seropositive individuals. J Infect Dis 211 (2015), 1712–1716.
10. [10] Théry, C., Duban, L., Segura, E., Véron, P., Lantz, O., Amigorena, S., Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 3 (2002), 1156–1162.
11. [11] Hao, S., Bai, O., Yuan, J., Qureshi, M., Xiang, J., Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol 3 (2006), 205–211.
12. [12] Colino, J., Snapper, C.M., Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen. J Immunol 177 (2006), 3757–3762.
13. [13] Colino, J., Snapper, C.M., Dendritic cell-derived exosomes express a Streptococcus pneumoniae capsular polysaccharide type 14 cross-reactive antigen that induces protective immunoglobulin responses against pneumococcal infection in mice. Infect Immun 75 (2007), 220–230.
14. [14] Viaud, S., Terme, M., Flament, C., et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Rα. PLoS One, 4, 2009, e4942.
15. [15] del Cacho, E., Gallego, M., Lillehoj, H.S., Quilez, J., Lillehoj, E.P., Sánchez-Acedo, C., Tetraspanin-3 regulates protective immunity against Eimeria tenella infection following immunization with dendritic cell-derived exosomes. Vaccine 31 (2013), 4668–4674.
16. [16] Bu, N., Wu, H., Zhang, G., et al. Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent T cell immune response against intracranial glioma in mice. J Mol Neurosci 56 (2015), 631–643.
17. [17] Vallhov, H., Gutzeit, C., Hultenby, K., Valenta, R., Grönlund, H., Scheynius, A., Dendritic cell-derived exosomes carry the major cat allergen Fel d 1 and induce an allergic immune response. Allergy 70 (2015), 1651–1655.
18. [18] Segura, E., Amigorena, S., Théry, C., Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis 35 (2005), 89–93.
19. [19] Segura, E., Nicco, C., Lombard, B., et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106 (2005), 216–223.
20. [20] Wiley, R.D., Gummuluru, S., Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A 103 (2006), 738–743.
21. [21] Izquierdo-Useros, N., Naranjo-Gómez, M., Erkizia, I., et al. HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse?. PLoS Pathog, 6, 2010, e1000740.
22. [22] Pontillo, A., Reis, E.C., da Silva, L.T., Duarte, A.J.S., Crovella, S., Oshiro, T.M., Dendritic cells used in anti-HIV immunotherapy showed different modulation in anti-HIV genes expression: new concept for the improvement of patients’ selection criteria. J Cell Immunother, 2016, 10.1016/j.jocit.2016.03.002.
23. [23] Théry, C., Amigorena, S., Raposo, G., Clayton, A., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol, 2006 [Chapter 3: Unit 3.22].
24. [24] Conde-Vancells, J., Rodriguez-Suarez, E., Embade, N., et al. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res 7 (2008), 5157–5166.
25. [25] Ostrowski, M., Carmo, N.B., Krumeich, S., et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 12 (2010), 19–30.
26. [26] Bobrie, A., Colombo, M., Krumeich, S., Raposo, G., Théry, C., Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J Extracell Vesicles, 1, 2012, 18397.
27. [27] Pant, S., Hilton, H., Burczynski, M.E., The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 83 (2012), 1484–1494.
28. [28] Li, M., Zeringer, E., Barta, T., Schageman, J., Cheng, A., Vlassov, A.V., Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers. Philos Trans R Soc Lond B Biol Sci, 369, 2014, 20130502.
29. [29] Øverbye, A., Skotland, T., Koehler, C.J., et al. Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget 6 (2015), 30357–30376.
30. [30] Alegre, E., Zubiri, L., Perez-Gracia, J.L., et al. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clin Chim Acta 454 (2015), 28–32.